Janssen reveals positive results from longest follow-up of Imbruvica
pharmafile | December 7, 2016 | News story | Research and Development | AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica
Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica (ibrutinib) had demonstrated an overall response rate of 89% in patients suffering from chronic lymphocytic leukaemia (CLL). The results from the trial also saw 29% of patients have a complete response to first-line treatment.
The drug was used in patients who suffered from CLL, which is a slow growing blood cancer that originates from B cells, a type of white blood cell. B cells play an important role in fighting infection in the body and those suffering from CLL experience a build of these cells within the lymphatic system.
Those patients who were treated with Imbruvica were found to have an improved rate of progression-free survival dependent upon how early they were treated with the drug. Overall survival for patients who received Imbruvica as their first-line treatment was recorded at 92%.
“The resounding evidence in support of ibrutinib’s benefits for patients continues to grow, and this longer-term data from five years of CLL treatment provides important reassurance of the lasting effect that can be achieved with ibrutinib over time,” said Jane Griffiths, company group chairman, Janssen Europe, Middle East and Africa. “We are so pleased to be altering the treatment landscape and changing what a diagnosis means for CLL patients, with these clinically significant improvements.”
Imbruvica is a drug co-developed between Cilag GmbH International, a subsidiary of Johnson & Johnson, and Pharmacyclics, a subsidiary of AbbVie.
Ben Hargreaves
Related Content
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England …
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …
